Gsk (GLAXF) Cost of Revenue (2009 - 2026)

Gsk's Cost of Revenue history runs 18 years deep, the most recent figure standing at $2.5 billion for Q1 2026.

• In Q1 2026, Cost of Revenue rose 3.61% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $20.5 billion (up 3.08% YoY), while the FY2025 annual figure was $11.9 billion, up 2.79% from the prior year.
• Cost of Revenue was $2.5 billion for Q1 2026 at Gsk, down from $12.0 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $12.0 billion in Q4 2025 to a low of $2.4 billion in Q1 2023.
• Historically, Cost of Revenue has averaged $4.8 billion across 5 years, with a median of $2.9 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue soared 59.85% in 2022, then sank 35.22% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $11.2 billion in 2022, then dropped by 5.14% to $10.6 billion in 2023, then rose by 9.24% to $11.6 billion in 2024, then increased by 3.28% to $12.0 billion in 2025, then tumbled by 78.92% to $2.5 billion in 2026.
• The last three Cost of Revenue figures came in at $2.5 billion (Q1 2026), $12.0 billion (Q4 2025), and $3.0 billion (Q3 2025), per Business Quant data.